Article
Oncology
Fengjiao Yao, Yacong An, Xialian Lai, Xundou Li, Zhen Yu, Xian-Da Yang
Summary: This study developed a novel nanotherapeutics for immune checkpoint blockade (ICB) immunotherapy by conjugating CTLA-4 aptamers to the surface of albumin nanoparticles and encapsulating fexofenadine (FEXO) into the aptamer-modified nanostructure. The results demonstrated that the aptamer-modified nanoparticles selectively bound to CTLA-4 positive cells and improved lymphocyte-mediated antitumor cytotoxicity in vitro, as well as enhanced antitumor immunity in animal studies. Furthermore, the drug-loaded nanoparticles further improved the antitumor efficacy compared to the aptamer-modified nanoparticles in vivo.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Chenglai Xia, Shuanghong Yin, Kenneth K. W. To, Liwu Fu
Summary: Cancer development is influenced by an immunosuppressive tumor microenvironment that weakens the immune response and allows tumors to evade detection. The enzymes CD39 and CD73 convert ATP into adenosine, which interacts with adenosine receptors to regulate immune function. Specifically, the A2AR receptor suppresses the immune system through cAMP signaling. CD39, CD73, and A2AR are potential therapeutic targets for enhancing antitumor immunity. Clinical trials are underway to investigate monoclonal antibodies and small molecule inhibitors that target the CD39/CD73/A2AR pathway, either alone or in combination with anti-PD-1/PD-L1 therapies.
Article
Multidisciplinary Sciences
Brianna M. Lax, Joseph R. Palmeri, Emi A. Lutz, Allison Sheen, Jordan A. Stinson, Lauren Duhamel, Luciano Santollani, Alan Kennedy, Adrienne M. Rothschilds, Stefani Spranger, David M. Sansom, K. Dane Wittrup
Summary: Anti-CTLA-4 antibodies have limited long-term benefit in tumor regression. We engineered a nonantagonistic CTLA-4 binding domain and found that both CTLA-4 antagonism and intratumoral Treg depletion are needed for maximum efficacy in anti-CTLA-4 therapy.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Review
Oncology
Hao Zhang, Ziyu Dai, Wantao Wu, Zeyu Wang, Nan Zhang, Liyang Zhang, Wen-Jing Zeng, Zhixiong Liu, Quan Cheng
Summary: The regulatory mechanisms of PD-L1 and CTLA-4 play a crucial role in immunotherapy, and understanding their interactions can help improve patients' treatment responses and clinical care.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, Research & Experimental
Shima Bastaki, Surendar Aravindhan, Nasrin Ahmadpour Saheb, Mahsa Afsari Kashani, Aleksei Evgenievich Dorofeev, Fariba Karoon Kiani, Hediyeh Jahandideh, Farzaneh Beigi Dargani, Mohsen Aksoun, Afshin Nikkhoo, Ali Masjedi, Ata Mahmoodpoor, Majid Ahmadi, Sanam Dolati, Simin Namvar Aghdash, Farhad Jadidi-Niaragh
Summary: The immunotherapy method using potential tumor microenvironment modulators showed promising therapeutic responses in cancer treatment. The delivery system designed to deliver small interfering RNAs to silence the targeted genes resulted in significant downregulation of PD-L1 and STAT3 genes, as well as notable effects on tumor cell proliferation, migration, and angiogenesis, and tumor growth in vivo.
Article
Immunology
B. Leticia Rodriguez, Limo Chen, Yanli Li, Shucheng Miao, David H. Peng, Jared J. Fradette, Lixia Diao, Jessica M. Konen, Frank R. Rojas Alvarez, Luisa M. Solis, Xiaohui Yi, Aparna Padhye, Laura A. Gibson, Joshua K. Ochieng, Xiaofei Zhou, Jing Wang, Don L. Gibbons
Summary: The resistance to immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) is associated with infiltrating monocytes, and controlling the differentiation process of monocytes can enhance the therapeutic potential of ICB.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Hongsheng Zhang, Jintao Mi, Qi Xin, Weiwei Cao, Chunjiao Song, Naidan Zhang, Chengliang Yuan
Summary: Breast cancer poses treatment challenges, but immunotherapy with immune checkpoint inhibitors shows promise. Research is ongoing to explore monotherapy and combination therapy approaches, while also investigating immune-related adverse events.
FRONTIERS IN ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Yuqian Feng, Huimin Jin, Kaibo Guo, Yuying Xiang, Yiting Zhang, Wurong Du, Minhe Shen, Shanming Ruan
Summary: The study supports the efficacy of combination therapy with immune checkpoint inhibitors (ICIs) in cancer treatment, especially showing longer PFS in patients with high PD-L1 expression. More high-quality clinical randomized controlled trials are needed in the future to confirm these findings, as the number of included trials was limited.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Immunology
Lujun Chen, Xiao Zheng, Hao Huang, Chen Feng, Shaoxian Wu, Rongzhang Chen, Hongwei Jiang, Maoling Yuan, Yuanyuan Fu, Hanjie Ying, Jun Zhou, Jingting Jiang
Summary: The strategy of combining immune checkpoint inhibitors (ICIs) with other therapies is important for enhancing cancer treatment. Cordycepin, an adenosine derivative, has shown promise in treating inflammation and cancer. Our research demonstrates that the combination of cordycepin and the anti-CD47 antibody effectively reduces tumor growth and extends the lifespan of tumor-bearing mice.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Afshin Derakhshani, Shahryar Hashemzadeh, Zahra Asadzadeh, Mahdi Abdoli Shadbad, Farnaz Rasibonab, Hossein Safarpour, Vahid Jafarlou, Antonio Giovanni Solimando, Vito Racanelli, Pankaj Kumar Singh, Souzan Najafi, Darya Javadrashid, Oronzo Brunetti, Nicola Silvestris, Behzad Baradaran
Summary: The study revealed an increasing trend of CTLA-4 in colorectal cancer (CRC) and the inhibitory molecule can be suppressed by the chemotherapy drug capecitabine. Inhibiting CTLA-4 can reactivate immune cells against tumors, potentially enhancing treatment outcomes.
Article
Chemistry, Multidisciplinary
Wenqian Yu, Junlin Sun, Xiuyuan Wang, Shuyi Yu, Mingzhu Yan, Fuan Wang, Xiaoqing Liu
Summary: This study reports a convenient tumor-specific A2AR inhibition strategy to improve antitumor immune responses using a photo-modulated nanoreactor for spatiotemporally controlled oxygen supply. This nanoreactor not only relieves A2AR-mediated immunosuppression, but also enhances antitumor immunity through photothermal ablation of the tumor and immunogenic cell deaths.
ADVANCED MATERIALS
(2022)
Article
Biochemistry & Molecular Biology
Amin Daei Sorkhabi, Aila Sarkesh, Ali Fotouhi, Hossein Saeedi, Leili Aghebati-Maleki
Summary: This study aimed to assess the effect of mono, dual, and triple combinations of CTLA-4, PD-L1, and TIM3 blockade on osteosarcoma cell viability, apoptosis, and migration. The results showed that triple blockade had the most significant impact on cell viability, apoptosis rate, and migration inhibition.
Article
Oncology
Kristina Witt, Susan Evans-Axelsson, Andreas Lundqvist, Martin Johansson, Anders Bjartell, Rebecka Hellsten
Summary: The combination of STAT3 inhibition with anti-CTLA-4 therapy enhances antitumoral activity in prostate cancer, reducing intratumoral Treg frequency.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Immunology
Farid Ghorbaninezhad, Javad Masoumi, Mohammad Bakhshivand, Amir Baghbanzadeh, Ahad Mokhtarzadeh, Tohid Kazemi, Leili Aghebati-Maleki, Siamak Sandoghchian Shotorbani, Mahdi Jafarlou, Oronzo Brunetti, Mariacarmela Santarpia, Behzad Baradaran, Nicola Silvestris
Summary: DC-based immunotherapy has gained interest in anti-cancer immunotherapies. However, the immunosuppressive mechanisms in the tumor environment, such as inhibitory immune checkpoint molecules, can reduce the efficacy of DC-mediated anti-tumoral immune responses. In this study, we found that blocking CTLA-4 expression on DCs promoted their stimulatory properties and resulted in increased T cell proliferation and cytokine production.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Engineering, Biomedical
Sukyung Song, Man Kyu Shim, Suah Yang, Jaewan Lee, Wan Su Yun, Hanhee Cho, Yujeong Moon, Jin Young Min, Eun Hee Han, Hong Yeol Yoon, Kwangmeyung Kim
Summary: This study proposes all-in-one glycol chitosan nanoparticles (CNPs) that can deliver anti-PD-L1 peptide (PP) and doxorubicin (DOX) to targeted tumor tissues for safe and effective synergistic immunotherapy.
BIOACTIVE MATERIALS
(2023)
Article
Biochemistry & Molecular Biology
Shiva Abolhasani, Seyyed Sina Hejazian, Vahid Karpisheh, Atefeh Khodakarami, Hamed Mohammadi, Jamshid Gholizadeh Navashenaq, Mohammad Hojjat-Farsangi, Farhad Jadidi-Niaragh
Summary: The discovery of new genes/pathways in cancer research provides novel therapeutic options, and understanding the roles and therapeutic potential of SF3B1 and NOTCH1 in leukemia pathogenesis is crucial for advancing leukemia treatment.
Article
Biochemistry & Molecular Biology
Armina Shirangi, Fatemeh Mottaghitalab, Sajad Dinarvand, Fatemeh Atyabi
Summary: A nanoparticle system for targeted delivery of ROR1 siRNA in the treatment of triple-negative breast cancer was designed and tested. The nanoparticles showed good properties and effectively suppressed tumor cell growth both in vitro and in vivo. The accumulation of nanoparticles in breast tumors was increased by magnetic field guidance. This therapeutic strategy has potential in the treatment of triple-negative breast cancer.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Article
Pharmacology & Pharmacy
Abbas Ali Hosseinpour Feizi, Sajjad Vakili-Samiani, Vahid Karpisheh, Ali Masjedi, Sepideh Izadi, Sara Adibfar, Afshin Nikkhoo, Mohammad Hojjat-Farsangi, Fatemeh Atyabi, Omid Joodi Khanghah, Ali Akbar Movassaghpour, Saeed Solali, Mehdi Yousefi, Farhad Jadidi-Niaragh
Summary: This study used TAT-PEG-CCMD nanoparticles to deliver anti-WEE1 siRNA and Dox to ALL cells, which effectively inhibited WEE1 kinase overexpression and enhanced the apoptotic effects of Dox. These findings suggest that this combination therapy could be a promising approach for treating ALL.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Medicine, Research & Experimental
Sara Adibfar, Ali Masjedi, Atefeh Nazer, Bentolhoda Rashidi, Vahid Karpisheh, Sepideh Izadi, Hadi Hassannia, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mohammad Hojjat-Farsangi, Hanieh Tarokhian, Farhad Jadidi-Niaragh
Summary: The study found that inhibiting CD73/EZH2 factors using SPION-TMC-FA NPs may be a promising strategy for treating breast cancer, reducing cancer development and enhancing anti-tumor immune responses.
Article
Obstetrics & Gynecology
Ramin Pourakbari, Forough Parhizkar, Mohammad Sadegh Soltani-Zangbar, Parisa Samadi, Majid Zamani, Leili Aghebati-Maleki, Roza Motavalli, Ata Mahmoodpoor, Farhad Jadidi-Niaragh, Bahman Yousefi, Hossein Samadi Kafil, Mohammad Hojjat-Farsangi, Shahla Danaii, Mehdi Yousefi
Summary: This study identifies the impact of preeclampsia (PE) exosomes on the activity of Th17 and Treg cells and their related gene expression and cytokine profiles in healthy pregnant women. PE patients exhibited decreased Treg cell number and increased Th17 cells, while intervention with PE exosomes led to significant changes in gene expression and cytokine levels. These findings suggest a possible role of PE exosomes in the pathogenesis of PE.
REPRODUCTIVE SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Mohammad Sadeghi, Atefeh Khodakarami, Armin Ahmadi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mehdi Yousefi, Mohammad Hojjat-Farsangi, Ali Akbar Movasaghpour Akbari, Farhad Jadidi-Niaragh
Summary: This article reviews the role of CTLA-4 in different subtypes of Hematological Malignancies (HMs), including its expression pattern, its effect on prognosis, and polymorphisms. The article also discusses the effects of targeting CTLA-4 in vitro, in vivo, and in clinical trials. According to recent literature, CTLA-4 is overexpressed in different HMs and is associated with poor survival, except in Chronic Lymphocytic Leukemia (CLL) where it is associated with better prognosis. Targeting CTLA-4 is helpful in certain HMs but not recommended in others. Certain CTLA-4 gene polymorphisms also play a significant role in the course of HMs. Future studies will further our understanding of the role of CTLA-4 in HMs.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2023)
Review
Chemistry, Multidisciplinary
Parichehr Hassanzadeh, Fatemeh Atyabi, Rassoul Dinarvand
Summary: The emerging pathological conditions and growing drug resistance call for the application of advanced technologies to discover therapeutic candidates and gain comprehensive understanding about their targets, action mechanisms, and interactions within the body. Physics- and chemistry-based techniques can be used for theranostic purposes, including preparing smart carriers, local drug or gene delivery, and enhancing pharmaceutical bioavailability. Crystal engineering and other techniques such as artificial intelligence and quantum-based methods can play a crucial role in manufacturing efficient pharmaceuticals and reducing adverse events.
JOURNAL OF CONTROLLED RELEASE
(2023)
Correction
Pharmacology & Pharmacy
Farhad Alvandifar, Baharnaz Ghaffari, Navid Goodarzi, Nazanin Shabani Ravari, Fahimeh Karami, Mohsen Amini, Effat Souri, Mohammad Reza Khoshayand, Mehdi Esfandyari-Manesh, Razieh Mohammad Jafari, Fatemeh Atyabi, Shiva Irani, Rassoul Dinarvand
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2023)
Retraction
Chemistry, Multidisciplinary
Armin Mahmoud Salehi, Farnaz Kheshti, Farnaz Hajizadeh, Asal Barshidi, Bentolhoda Rashidi, Farbod Ebrahimi, Simin Bahmanpour, Vahid Karpisheh, Fatemeh Karimian Noukabadi, Fariba Karoon Kiani, Hadi Hassannia, Fatemeh Atyabi, Seyed Hossein Kiaie, Fatah Kashanchi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Rafieh Bagherifar, Reza Jafari, Naime Majidi Zolbanin, Farhad Jadidi-Niaragh
PHARMACEUTICAL RESEARCH
(2023)
Review
Cell Biology
Mohammad Sadeghi, Mehrdad Fathi, Jamshid Gholizadeh Navashenaq, Hamed Mohammadi, Mehdi Yousefi, Mohammad Hojjat-Farsangi, Afshin Namdar, Ali Akbar Movasaghpour Akbari, Farhad Jadidi-Niaragh
Summary: Heme oxygenase-1 (HO-1) is overexpressed in hematological malignancies and associated with disease severity. It induces tumor progression and prevents apoptosis through various pathways, making it a potential therapeutic target. However, the exact role of HO-1 in Chronic Lymphocytic Leukemia (CLL) remains unclear.
CELL COMMUNICATION AND SIGNALING
(2023)
Article
Biochemistry & Molecular Biology
Soha Habibi, Toraj Mohammadi, Romina HMTShirazi, Fatemeh Atyabi, Melika Kiani, Amir Atabak Asadi
Summary: In this study, double-layer CS/PVA/mupirocin (CPM) + CS/PVA/bupivacaine (CPB) electrospun nanofiber mats were prepared and crosslinked to optimize their water-resistant and biodegradation properties. The mats exhibited defect-free and interconnected nanofibers, providing a moist environment for efficient wound breathing and repairing. The highly porous mat absorbed wound exudates and allowed air permeability, reducing the chance of bacterial infections.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Pharmacology & Pharmacy
Seyed Reza Heydari, Mahnoush Samadi, Armina Shirangi, Mehdi Farokhi, Ayda Moradi, Reza Bafkary, Fatemeh Atyabi, Fatemeh Mottaghitalab, Rassoul Dinarvand
Summary: In this study, dual responsive mesoporous silica nanoparticles (MSNs) were designed to effectively deliver PB to osteosarcoma cancer cells. PB loaded MSNs showed higher drug release in the tumor microenvironment and enhanced cytotoxicity against cancer cells. This study provides a promising method for osteosarcoma treatment using PB loaded MSNs.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Nazanin Shabani Ravari, Maryam Ghareh Sheikhlou, Navid Goodarzi, Bahar Kharazian, Mohsen Amini, Fatemeh Atyabi, Saman A. A. Nasrollahi, Rassoul Dinarvand
Summary: Researchers used CPP as a carrier to create CPP-BoNT/A nanocomplexes by PEC method, aiming to increase toxin entrapment, reduce diffusion, and prolong the effect. The nanocomplexes showed higher cellular toxicity than the toxin and had a slower onset and longer duration of action on muscles.
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Amineh Ghaderi, Mohammad-Ali Okhovat, Jemina Lehto, Luigi De Petris, Ehsan Manouchehri Doulabi, Parviz Kokhaei, Wen Zhong, Georgios Z. Rassidakis, Elias Drakos, Ali Moshfegh, Johan Schultz, Thomas Olin, Anders Osterborg, Hakan Mellstedt, Mohammad Hojjat-Farsangi
Summary: This study evaluated the expression of ROR1 in NSCLC patients and the cytotoxic effects of a small molecule ROR1 inhibitor in NSCLC cell lines. ROR1 was overexpressed in non-squamous and squamous carcinomas, as well as neuroendocrine tumors. The ROR1 inhibitor dephosphorylated ROR1 and induced apoptosis, and also inhibited the proliferation and migration of NSCLC cells. The combination of the ROR1 inhibitor and EGFR inhibitor showed a synergistic apoptotic effect.
Article
Ophthalmology
Elham Delrish, Mahmoud Jabbarvand, Fariba Ghassemi, Fahimeh Asadi Amoli, Fatemeh Atyabi, Saeed Heidari Keshel, Alireza Lashay, Farnaz Sadat Mirzazadeh Tekie, Masoud Soleimani, Rassoul Dinarvand
Summary: This study aimed to evaluate the efficacy of thiolated chitosan-dextran nanoparticles (TPH-CMD-TCS-NPs) in improving intravitreal chemotherapy of retinoblastoma in a rabbit xenograft model. The results showed that the NPs had a mean diameter of 30 +/- 4 nm, a polydispersity index of 0.24 +/- 0.03, and a zeta potential of +10 +/- 3 mV. The TPH-CMD-TCS-NPs group showed a significant decrease in tumor volume compared to the control group (P = 0.039).
JOURNAL OF OPHTHALMIC & VISION RESEARCH
(2023)